Bitcoin Updates: MSCI's Uncertainty in Classifying Bitcoin Puts MSTR's $59 Billion Worth at Risk
- MSCI's proposed exclusion of MSTR from major indices could trigger $2.8B in outflows, destabilizing its leveraged Bitcoin model. - JPMorgan warns the move reflects a debate over classifying Bitcoin-holding firms as investment vehicles, not operating businesses. - MSTR's stock has fallen 60% since November 2024, with its NAV multiple collapsing to 1.1 as Bitcoin prices drop 30%. - Saylor continues aggressive Bitcoin buying ($1.5B in November) via equity/dilutive debt, straining investor confidence and pus
Michael Saylor's
The move to exclude Strategy is rooted in an ongoing debate about whether companies like it, which primarily hold
Even amid market volatility, Saylor has continued to rapidly increase the company’s Bitcoin reserves. In November alone, Strategy purchased $1.5 billion worth of Bitcoin, raising its total holdings to 640,808 BTC as of November 17,
Saylor, nevertheless, remains optimistic. In a recent interview, he shared an ambitious plan to amass a $1 trillion Bitcoin balance sheet,
As the January deadline nears, Strategy’s situation highlights the fragile nature of index inclusion in today’s markets. What once amplified Saylor’s story now threatens to unravel it,
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Polkadot Latest Updates: ECB Raises Concerns: Cryptocurrency and Stock Market Downturns Resemble Dot-Com Bubble Threats
- ECB warns U.S. equity/crypto corrections threaten stability, urging central banks to retain rate-cut flexibility amid market volatility. - JPMorgan links crypto ETF outflows to retail investor behavior, noting $4B November sales contrast with $96B equity ETF inflows. - U.S. Treasury downplays recession risks, citing 2026 growth optimism despite shutdown impacts and services-driven inflation. - MSCI highlights tech valuation risks akin to dot-com era, while DeFi faces $12B liquidity crisis with 95% capita

Novartis Increases 2030 Growth Projections Despite Analysts' Concerns About Patent Threats
- Novartis raised 2030 sales growth targets to 5-6% annually, driven by high peak sales expectations for oncology drugs Kisqali and Scemblix. - CEO Vas Narasimhan highlighted eight de-risked drugs with $3-10B peak potential, but analysts warned of patent expirations and uncertain pipeline progress beyond 2030. - Shares rose 0.5% post-announcement, while Exact Sciences surged 17% on its $105/share acquisition by Abbott and Samsung Biologics saw a 71% valuation re-rating after spin-off. - J.P. Morgan caution

Institutional Blockchain Integration: Blockdaemon and 21shares Bridge Traditional Finance and Web3 through the Canton Network
- Blockdaemon's Institutional Vault now supports Canton Coin, enabling secure custody and tokenization for institutions on the Canton Network. - 21shares launched a Canton Coin ETP on Euronext, offering investors institutional-grade exposure to privacy-focused blockchain innovation. - Canton Network's architecture, backed by J.P. Morgan and Goldman Sachs , facilitates secure, interoperable transactions while maintaining regulatory compliance. - Partnerships between blockchain infrastructure providers and t

LINK Price Moves to $13.90 as Market Tracks Tight Short-Term Structure
